Jose María Villagran

Dr. Jose María Villagran


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2017 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
AGAB-GEN Collaborative Group
AB-GEN Collaborative Group
VSVíctor Pérez Sola
Víctor Pérez Sola
ASAriana Salavert
Ariana Salavert
JEJordi Espadaler-Mazo
Jordi Espadaler-Mazo
MTMiquel Tuson
Miquel Tuson
JMJosé M. Menchón
José M. Menchón
A 12-week, double-blind, parallel, multi-center randomized controlled trial in 316 adult patients with major depressive disorder (MDD) was conducted to evaluate the effectiveness of pharmacogenetic (PGx) testing for drug therapy guidance. Patients with a CGI-S ≥ 4 and requiring antidepressant medication de novo or changes in their medication regime were recruited at 18 Spanish public hospitals, genotyped with a commercial PGx panel (Neuropharmagen®), and randomized to PGx-guided treatment (n = 155) or treatment as usual (TAU, control group, n = 161), using a computer-generated random list that locked or unlocked psychiatrist access to the results of the PGx panel depending on group allocation. The primary endpoint was the proportion of patients achieving a sustained response (Patient Global Impression of Improvement, PGI-I ≤ 2) within the 12-week follow-up. Patients and interviewers collecting the PGI-I ratings were blinded to group allocation. Between-group differences were evaluated using χ2-test or t-test, as per data type. Two hundred eighty patients were available for analysis at the end of the 12-week follow-up (PGx n = 136, TAU n = 144). A difference in sustained response within the study period (primary outcome) was not observed (38.5% vs 34.4%, p = 0.4735; OR = 1.19 [95%CI 0.74-1.92]), but the PGx-guided treatment group had a higher responder rate compared to TAU at 12 weeks (47.8% vs 36.1%, p = 0.0476; OR = 1.62 [95%CI 1.00-2.61]), and this difference increased after removing subjects in the PGx-guided group when clinicians explicitly reported not to follow the test recommendations (51.3% vs 36.1%, p = 0.0135; OR = 1.86 [95%CI 1.13-3.05]). Effects were more consistent in patients with 1–3 failed drug trials. In subjects reporting side effects burden at baseline, odds of achieving a better tolerability (Frequency, Intensity and Burden of Side Effects Rating Burden subscore ≤2) were higher in the PGx-guided group than in controls at 6 weeks and maintained at 12 weeks (68.5% vs 51.4%, p = 0.0260; OR = 2.06 [95%CI 1.09-3.89]). PGx-guided treatment resulted in significant improvement of MDD patient’s response at 12 weeks, dependent on the number of previously failed medication trials, but not on sustained response during the study period. Burden of side effects was also significantly reduced. European Clinical Trials Database 2013-002228-18 , registration date September 16, 2013; ClinicalTrials.gov NCT02529462 , retrospectively registered: August 19, 2015.


12 June 2020
Verified
Book Chapter
Closed access
PDF file
JVJose María Villagran
Jose María Villagran
RLRogelio Luque
Rogelio Luque

12 June 2020
Verified
Book Chapter
Closed access
PDF file
RLRogelio Luque
Rogelio Luque
JVJose María Villagran
Jose María Villagran

26 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JPJose Guzman Parra
Jose Guzman Parra
JDJonathan Joseph Dawood-Hristova
Jonathan Joseph Dawood-Hristova
BIBlanca Iglesias-Rosado
Blanca Iglesias-Rosado
Carlos Aguilera-SerranoCarlos Aguilera-Serrano
Carlos Aguilera-Serrano
Jesús Herrera-ImbrodaJesús Herrera-Imbroda
Jesús Herrera-Imbroda
GGGloria Pérez Guerrero
Gloria Pérez Guerrero
Background: Mechanical restraint remains a common coercive practice in acute psychiatric wards and is particularly concerning in older adults due to greater physical and cognitive vulnerability. Methods: We conducted a retrospective observational study using routinely collected registry data from all recorded mechanical restraint episodes in 20 acute adult mental health inpatient units in the Andalusian public health system over 30 months. Among 2,435 restrained individuals with documented age, 19.4% (n=473) were ≥55. Age was modelled as a continuous predictor of (i) repeated restraint (any subsequent episode) and (ii) multiple restraints (≥3 episodes) using mixed-effects logistic regression with random intercepts for unit and adjustment for sociodemographic, diagnostic, and episode-related factors. Results: Compared with younger users, older restrained users were more often female and Spanish, more frequently had bipolar disorder and organic/intellectual disability diagnoses, and less often had substance use or personality disorders. They experienced a longer time from admission to the first restraint. Restraint was more often recorded as “required for another therapeutic activity” and less often due to “aggressive behavior”. During restraint, older users more frequently displayed confusion, and episodes more often began at night. Repeated restraint occurred in 27.2% of subjects; younger age was significant in univariable analysis but not after adjustment (aOR 1.004). Multiple restraint occurred in 23.0%; after adjustment, older age was associated with lower odds (aOR 0.992). Conclusions: Older adults showed a distinct restraint profile, supporting age-sensitive restraint-reduction strategies focused on frailty/confusional states in older individuals and preventing repeated episodes in younger users.